|
Jul 25
|
TRYNGOLZA® (olezarsen) recommended for EU approval by CHMP for familial chylomicronemia syndrome (FCS)
|
|
Jul 25
|
Sobi Announces U.S. Food and Drug Administration Approves Doptelet® (avatrombopag) for the Treatment of Thrombocytopenia in Pediatric Patients One Year and Older with Persistent or Chronic Immune Thrombocytopenia (ITP)
|
|
Jul 16
|
Sobi publishes Q2 2025 report: Continued strong portfolio and pipeline momentum
|
|
Jul 15
|
The Board of Directors of Sobi exercises authorisation for repurchase of shares for the purpose of securing the company's commitments under incentive programmes
|
|
Jun 20
|
Sobi will showcase extensive research and clinical outcomes at ISTH 2025
|
|
May 28
|
Sobi to share new clinical data and research at EULAR 2025
|
|
Apr 15
|
Invitation: Sobi's Q1 report
|
|
Feb 20
|
EMA validates indication extension application for Aspaveli® for treatment of C3G and primary IC-MPGN
|
|
Feb 20
|
Apellis and Sobi Announce EMA Validation of Indication Extension Application for Aspaveli® (pegcetacoplan) for C3G and Primary IC-MPGN
|
|
Oct 9
|
Invitation: Sobi's Q3 2024 report
|
|
Jun 19
|
European Commission grants Sobi® Marketing Authorisation for ALTUVOCT™ for treatment of haemophilia A
|
|
Apr 26
|
Sobi® receives positive CHMP opinion recommending approval of efanesoctocog alfa for once-weekly treatment of haemophilia A
|
|
Apr 25
|
Sobi Q1 2024 report: Strong sales reflecting the strength of the portfolio
|
|
Apr 4
|
Notice of Annual General Meeting in Swedish Orphan Biovitrum AB (publ)
|
|
Jan 5
|
Sobi's Chairman of the Board resigns due to health reasons
|
|
Nov 30
|
Change in number of shares and votes in Swedish Orphan Biovitrum AB (publ)
|